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Hemostatic Abnormalities in Uncomplicated Babesiosis
(Babesia rossi) in Dogs
C. Liebenberg, A. Goddard, B. Wiinberg, M. Kjelgaard-Hansen, L.L.van der Merwe, P.N. Thompson,
P.T. Matjila, and J.P. Schoeman
Background: Babesiosis in dogs is associated with severe thrombocytopenia; yet infected dogs rarely show clinical signs
of hemorrhage.
Hypothesis: Dogs with uncomplicated babesiosis have normal hemostatic capacity despite severe thrombocytopenia.
Animals: Nineteen client-owned dogs with uncomplicated babesiosis; 10 healthy controls.
Methods: A prospective, cross-sectional, observational study. Thromboelastography (TEG), prothrombin time (PT),
activated partial thromboplastin time (aPTT), ﬁbrinogen, D-dimers, and antithrombin (AT) measured in both groups. Sta-
tistical signiﬁcance set at P < .01.
Results: Babesiosis group hematocrit and platelet count signiﬁcantly lower than controls (0.29 versus 0.50 L/L;
P < .001 and 20.0 versus 374.5 9 109/L; P < .001, respectively). Except for K, no signiﬁcant diﬀerence in TEG variables
between groups. Hemostatic variables for babesiosis group versus controls (mean ± SD); R: 5.9 ± 1.8 versus 4.6 ± 0.9 min
(P = .048); K: 2.8 ± 1.1 versus 1.9 ± 0.6 min (P = .003); angle: 55.5 ± 11.7 versus 62.2 ± 4.1 degrees (P = .036);
MA: 48.4 ± 9.7 versus 57.2 ± 5.2 mm (P = 0.013); G: 5.1 ± 1.9 versus 6.9 ± 1.5 dyn/cm2 (P = .019); LY30 (median, range):
0 (0–5.7) versus 0.6% (0–6.1) (P = .152); and LY60: 0 (0–8.8) versus 3.1% (0–13.1) (P = .012). AT activity signiﬁcantly
lower (105.2 ± 16.5 versus 127.8 ± 15.4%; P = .001). Fibrinogen concentration signiﬁcantly higher in babesiosis group
(5.7 ± 1.3 versus. 3.0 ± 0.7 g/L; P < .001).
Conclusion and Clinical Importance: Despite severe thrombocytopenia, dogs with uncomplicated babesiosis did not have
clinical signs of hemorrhage and TEG variables were normal, which could indicate a normocoagulable state.
Key words: Coagulation; Platelets; Thromboelastography.
Babesiosis, caused by Babesia rossi, is a commoncause of morbidity and death of dogs in South
Africa. Babesiosis in dogs can be classiﬁed as uncom-
plicated or complicated based on the degree of anemia
and the severity of the presenting clinical signs.1,2 In
uncomplicated babesiosis the clinical signs are mostly
attributable to the degree of the anemia, whereas in
complicated babesiosis the disease process is character-
ized by additional organ involvement.3,4 One of the
most common hematological hallmarks of babesiosis
in dogs is thrombocytopenia, which is not associated
with clinical hemorrhage despite low platelet counts
that would normally cause inability to maintain nor-
mal primary hemostatic function.5,6
Several routine laboratory assays are traditionally
utilized to diagnose and monitor abnormalities associ-
ated with hemostasis. These assays include platelet
count and platelet function assays to evaluate primary
hemostasis and prothrombin time (PT), activated
partial thromboplastin time (aPTT), ﬁbrin(ogen) deg-
radation products (FDP), D-dimer concentration, anti-
thrombin (AT) activity, and ﬁbrinogen concentration
to evaluate secondary hemostasis and ﬁbrinolysis.7
Limitations associated with the majority of these
assays are their insensitivity to identify the early onset
of hemostatic abnormalities, as well as the fact that
each assay only evaluates a speciﬁc part of the hemo-
static pathway.
Systemic inﬂammatory response syndrome (SIRS) is
a well-described consequence of babesiosis8 and one of
the key components of SIRS is the activation of an
acute phase response with markedly increased plasma
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Abbreviations:
aPTT activated partial thromboplastin time
AT antithrombin
CBC complete blood count
FDP ﬁbrin degradation products
G global clot strength
Ht hematocrit
K clotting time
LY30 percent lysis at 30 minutes
LY60 percent lysis at 60 minutes
MA maximal amplitude
PCR polymerase chain reaction
PT prothrombin time
RLB reverse line blot
R reaction time
SIRS systemic inﬂammatory response syndrome
TEG thromboelastography
a angle
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concentrations of ﬁbrinogen.9,10 Several studies have
reported that inﬂammation can activate hemosta-
sis.11,12 The etiology has been extensively studied and
the interactions between these 2 systems are best illus-
trated with the cell-based model of hemostasis.13 Few
assays are available that accurately reﬂect the interac-
tions between inﬂammation and hemostasis, but
thromboelastography (TEG) incorporates the interac-
tions of all the important intravascular components of
the hemostatic system, except the endothelium, and is
believed to be a closer approximation of hemostasis as
it occurs in vivo.14 TEG is inﬂuenced by hematocrit
(Ht), platelet count, platelet function, ﬁbrinogen con-
centration, and AT activity.14–16 The platelet function
is measured as the overall clot strength (MA), which is
primarily dependent on the cross binding of platelets
and ﬁbrinogen. Importantly, with respect to the low
platelet count seen in babesiosis, platelet concentration
aﬀects the MA and several studies have reported that
a decreased platelet count leads to hypocoagulable
thromboelastograms.17–19 Equally important is the
data from in vitro studies in people which have shown
that MA can be normalized in severe thrombocytope-
nia, with platelet counts as low as 10 9 109/L, by
addition of ﬁbrinogen.20 To the authors’ knowledge,
TEG is one of the only methods available to measure
the interaction between platelets and ﬁbrinogen in
whole blood—an interaction which might well be cru-
cial for the absence of clinical hemorrhage in the face
of severe thrombocytopenia, seen in babesiosis.
The aim of this study was to describe the thrombo-
elastograms in uncomplicated babesiosis in dogs and
compare them with those of normal, healthy control
dogs. We hypothesized that these dogs would have a
normal hemostatic capacity, despite the severe throm-
bocytopenia, and that this could be measured with
TEG.
Materials and Methods
Study Design
This study was approved by the Animal Use and Care Com-
mittee of the University of Pretoria. It was performed as a pro-
spective, cross-sectional, observational study. A total of 29 dogs
were enrolled in this study: 19 client-owned dogs diagnosed with
uncomplicated babesiosis and 10 healthy client-owned dogs. Only
uncomplicated cases were included in an attempt to standardize
the study and limit variability. The control dogs were selected to
match (age and sex) that of the dogs with babesiosis. Owner con-
sent was obtained for all the cases for enrollment in this study.
Inclusion and Exclusion Criteria
Eligible dogs were of any breed and either sex, provided they
were  6 months of age, weighed more than 6 kg, and were
naturally infected by B. rossi parasites. Babesia rossi infection
was conﬁrmed and coinfection with Ehrlichia canis was ruled out
using a Polymerase Chain Reaction (PCR) and Reverse Line Blot
(RLB). None of the dogs that were included showed any clinical
evidence of a hemorrhagic tendency. Dogs were excluded if
they had any clinical or laboratory evidence of complications
associated with babesiosis, which included acute kidney failure,
neurological signs, acute respiratory distress syndrome, hemocon-
centration, secondary immune mediated hemolytic anemia, and
icterus. Dogs were also excluded if any concurrent inﬂammatory
disease conditions, any known cardiac disease, any known neoplastic
disease, any obvious infections or wounds, or any signs of trauma (such
as fractures, contusions, and wounds indicating a motor vehicle acci-
dent or ﬁghting) were present. Treatment with any medication known
to interfere with normal hemostasis including prednisolone, aspirin,
nonsteroidal anti-inﬂammatory drugs, or heparin products either at
presentation or 4 weeks prior to presentation were also reason
for exclusion. The controls included 10 healthy, client-owned
dogs, admitted for routine ovariohysterectomy, castration, or
blood donation. The controls were deemed healthy based on
history, a full clinical examination which included a peripheral
blood smear, as well as PCR and RLB to rule out blood-borne
parasites.
Sampling
Prior to any treatment, a serum sample (3 mL vacutainer
tubea), sodium citrate sample (3 mL vacutainer tube), and EDTA
sample (3 mL vacutainer tube) were collected from the jugular
vein of each dog, with a 21-gauge venoject needle by careful veni-
puncture with minimum stasis. Suﬃcient blood was collected in
the citrate tube to ensure a 1 : 9 ratio of 3.2% trisodium citrate
and blood. The blood samples were collected in the order
described above. The EDTA sample was used to determine the
platelet count and Ht. The TEG analysis was performed on the
sodium citrate sample 30 minutes after collection. The remaining
citrated sample was then centrifuged at 2100 9 g for 8 minutes,
after which the plasma was harvested and stored at 80°C. The
coagulation proﬁle analyses were performed as a batch within
4 months of collection and included PT, aPTT, D-dimer, AT and
ﬁbrinogen. Studies in people and dogs have reported that coagu-
lation proteins in frozen plasma remain stable between 6 and 24
months at 70°C.21,22.
Thromboelastography Analysis
The TEG analyses were performed 30 minutes after blood
sampling using a thromboelastographb according to a previously
published method.16 Several values are derived from the throm-
boelastogram. The reaction time (R) or precoagulation time is
related to the plasma clotting factors and inhibitor activity. The
clotting time (K) represents the rate of thrombin generation and
is aﬀected by clotting factors, ﬁbrinogen, and platelets. Angle (a)
represents the rate of ﬁbrin build-up and cross linking similar to
K and is aﬀected by the same factors. The maximal amplitude
(MA) represents the strength of the ﬁbrin clot and is aﬀected by
ﬁbrin and ﬁbrinogen concentration, platelet count and function,
thrombin concentration, factor XIII and Ht. The MA is also a
measure of clot stiﬀness and may be used to derive the global
clot strength (G), a measure of the overall coagulant state. The
G value is derived by the calculation: G = 5000 9 MA/
(100–MA) dyn/cm2. Using the G value one can characterize
thromboelastograms as hyper-, normo-, or hypocoagulable.14
Previous studies have reported G < 3.2 dyn/cm2 as hypocoagulable
and >7.2 dyn/cm2 as hypercoagulable.23 The LY30 and LY60 values
indicate the degree of ﬁbrinolysis at 30 and 60 minutes after MA
is reached.24
Coagulation Assays
A complete blood count (CBC) was performed to determine the
Ht and platelet count of each dog.c The PT and aPTT assays as well
as the ﬁbrinogen were performed on an automated hemostasis
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analyzerd with speciﬁc reagent kits for each analysis.e,f,g The
D-dimer concentration was determined using an immunometric ﬂow-
through principle.h AT activity in the plasma was measured utilizing a
thrombin dependent chromogenic substrate assayi on an automated
analyzer. All assays were calibrated according to the manufacturers’
recommendations for human purposes. Commercially available
human control reagents for the respective assays were analyzed
as internal controls together with pooled plasma from 5 healthy
dogs.
DNA Extraction and PCR
DNA was extracted from 200 lL of each whole blood sample
using the QIAmp® blood and tissue extraction kitj according to
the manufacturer’s instructions. Molecular diagnosis of B. rossi
and exclusion of other Babesia species, Ehrlichia, and Anaplasma
species was performed using PCR and RLB assay as previously
described.25,26
Statistical Analysis
Data were analyzed using Stata 12.1 statistical softwarek The
normality assumption was evaluated using the Shapiro-Wilk test
and equality of variances was evaluated using Levene’s test.
Diﬀerences between the babesiosis group and the control group
were tested using the Students t-test for normally distributed
variables or the Mann-Whitney-U-test for non-normally
distributed variables. Multiple linear regression analyses were
performed within the babesiosis group to estimate the association
of platelet count, Ht and ﬁbrinogen with the various TEG variables.
For this purpose, platelet count and Ht were log-transformed to
achieve normality. The regression models were evaluated using
residual versus ﬁtted plots and normal probability plots of residuals.
Signiﬁcance was set at P < .01 to reduce the risk of a family wise
Type I error rate in this multiple comparison setting.
Results
The age for the babesiosis group was 6 years
(7 months-11 years; median, range) and the group
consisted of 11 females and 8 males. Breeds included
four rottweilers, three Boerboels, two cross breed dogs,
two Jack Russell terriers, two dachshunds and one of
each of the following, fox terrier, toy pomeranian,
Labrador retriever, Staﬀordshire terrier, Chow–chow
and maltese. The age for the control group was
3.25 years (6 months-6 years) and it consisted of 6
females and 4 males. Breeds included three beagles,
two Boerboels, two German shepherd dogs and one of
each of the following, Rhodesian ridgeback, Bouvier
des Flanders and a cross breed.
Except for the mean K, which was longer in the
babesiosis than in the control group, there were no sig-
niﬁcant diﬀerences in the TEG variables (mean R,
angle, MA, G, and median LY30 and LY60) between
the groups. Three dogs with babesiosis had G values in
the hypercoagulable range (>7.2 dyn/cm2) according to
previous studies23 i.e., 9.25, 8.50, and 7.65 dyn/cm2,
respectively. The hematocrit and platelet count, and
AT activity were signiﬁcantly lower in the babesiosis
group compared to the control group. No signiﬁcant
platelet aggregation, which could have contributed to
the low platelet count, was reported in the samples.
The ﬁbrinogen concentration was signiﬁcantly higher
in dogs with babesiosis compared to the control group,
but the median D-dimer concentration was not signiﬁ-
cantly diﬀerent. PT was not signiﬁcantly diﬀerent
between the two groups (P = .076), but the aPTT was
signiﬁcantly prolonged in the babesiosis group
(P = .001). (Table 1).
Within the dogs with babesiosis, multiple regression
analysis revealed a signiﬁcant positive log-linear associa-
tion between platelet count and MA (r2 = 25.19;
P < .001) and platelet count and G (r2 = 5.30; P < .001);
and a signiﬁcant negative log-linear association between
platelet count and K (r2 = 2.10; P = .002). (Table 2)
These are shown at the univariable level in the scatter
plots of platelet count, Ht and ﬁbrinogen versus G.
(Fig. 1A–C) There were no signiﬁcant associations
Table 1. Mean (range) of the coagulation measures for the dogs with uncomplicated babesiosis and the healthy
control groups with respective P-values. Median (range) shown for hematocrit, platelet count, LY30, LY60, PT
and D-dimer concentration.
Parameter (unit)(Reference range) Babesiosis GroupMean/Median (Range) Control GroupMean/Median (Range) P-Value
Plt (109 /L) (200–500) 20.0 (8.0–120.0) 374.5 (224.0–678.0) <.001
Ht (L/L) (0.37–0.55) 0.29 (0.16–0.54) 0.50 (0.38–0.59) <.001
R – time (minutes) (3–9) 5.9 (2.0–8.5) 4.6 (3.7–6.0) .048
K – time (minutes) (2–8) 2.8 (1.2–4.4) 1.9 (1.5–2.3) .003
Angle (degrees) (27–59) 55.5 (33.6–71.3) 62.2 (56.6–70.2) .036
MA (mm) (39–59) 48.4 (31.6–64.9) 57.2 (48.7–65.9) .013
G (dyn/cm2) (3.2–7.2) 5.1 (2.4–9.3) 6.9 (4.9–10.0) .019
LY30 (%) (0–2) 0.0 (0.0–5.7) 0.6 (0.0–6.1) .152
LY60 (%) (0–8) 0.0 (0.0–8.8) 3.1 (0.0–13.1) .012
PT (seconds) (<6.9) 6.5 (5.5–8.1) 6.9 (6.3–11.7) .076
aPTT (seconds) (<12.9) 13.3 (10.4–15.5) 11.3 (9.2–12.5) .001
AT (%) (80–135) 105.2 (70.4–143.5) 127.8 (109.4–159.4) .001
Fibrinogen (g/L) (2–4) 5.7 (3.1–7.9) 3.0 (1.9–4.4) <.001
D-dimers (mg/L) (<0.5) 0.3 (0.1–1.0) 0.1 (0.1–0.3) .015
Platelet count (Plt); Hematocrit (Ht); Reaction time (R); Clotting time (K); Angle (a);Maximal amplitude (MA); Global clot strength
(G); Percent lysis at 30 minutes (LY30); Percent lysis at 60 minutes (LY60); activated partial thromboplastin time (aPTT); Prothrombin
time (PT); Antithrombin (AT).
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between Ht or ﬁbrinogen and any of the TEG variables.
Residual plots showed no obvious deviations from the
assumptions of normality, linearity or homoscedasticity
for any of the models. AT was not included in these
models since the mean AT was still well above reference
range despite being signiﬁcantly lower in the babesiosis
group (P = .001).
Discussion
This study demonstrated that, except for K, there
was no signiﬁcant diﬀerence in any of the TEG vari-
ables between the babesiosis group with a median
platelet count of 20 9 109/L and a control group con-
sisting of healthy dogs with normal platelet counts.
One of the hematological hallmarks of babesiosis in
dogs, caused by B. rossi, is thrombocytopenia, which
is not associated with clinical hemorrhage despite
platelet counts that would normally cause an inability
to maintain normal primary hemostatic function.5,6
TEG thus demonstrated that dogs with severe throm-
bocytopenia secondary to uncomplicated B. rossi infec-
tion may have normal overall hemostatic function,
which correlates with the clinical presentation.
An adequate number of normally functioning plate-
lets are vital for primary hemostasis and platelet
counts below 66 9 109/L have been shown to aﬀect
the TEG variables K, MA, and G in studies conducted
in both people and dogs.17,19,23,27 However, despite a
median platelet count of 20 9 109/L, the thromboelas-
tograms of the babesiosis group in this study did not
have a mean K, MA, or G below the reference interval.
In fact, 3 Babesia-infected dogs with severe throm-
bocytopenia had an increased G (G > 7.2 dyn/cm2),
suggesting hypercoagulability.23 This study showed
that there was a signiﬁcant positive association
between platelet count and MA and platelet count and
G, and a signiﬁcant negative association between plate-
let count and K, indicating that the lower the platelet count,
the relatively more hypocoagulable the thromboelastogram.
However, these ﬁndings were of no clinical signiﬁcance since
the mean values for the TEG variables in the babesiosis
group remained within the normal reference ranges. The
authors believe that the most likely explanation for
this ﬁnding is due to the eﬀect of marked platelet
activation, subsequent to the systemic inﬂammation,
providing a procoagulant membrane surface upon
which coagulation factors assemble. Thus, the babesiosis
group exibited a relative hypercoagulable state, com-
pared to what is normally seen in dogs with such
Table 2. Summary of results of multiple linear regression models of the association of log platelet count, log Ht,
and ﬁbrinogen with TEG variables (R, K, angle, MA, and G) in uncomplicated Babesia-infected dogs.
Predictors
Outcome [Regression Coeﬃcient (P-value)]
R K Angle MA G
log10 Plt 0.07 (0.965) 2.10 (0.002) 14.30 (0.113) 25.19 (<0.001) 5.30 (<0.001)
log10 Ht 2.16 (0.577) 3.28 (0.025) 25.90 (0.227) 0.93 (0.948) 1.23 (0.677)
Fibrinogen 0.38 (0.349) 0.06 (0.674) 0.87 (0.689) 0.95 (0.527) 0.21 (0.496)
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Fig 1. Scatter plots illustrating the associations of (A) platelet
count, (B) Ht, and (C) ﬁbrinogen with G.
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extremely low platelet counts, which explains the nor-
mal TEG variables. Both B. canis and B. rossi cause a
systemic inﬂammatory response with increased C-reac-
tive protein, hyperﬁbrinoginemia, thrombocytopenia,
and leukopenia.8,9,28 Inﬂammation promotes coagula-
tion and thrombin can in turn cause inﬂammation.29
Although platelets are activated by many stimuli,
thrombin is the most potent platelet activator.30 Plate-
let activation and the coagulation cascade collectively
determine the hemostatic activity of plasma—both are
intertwined and thrombin is instrumental in each
process.13,31
This study showed that there were no signiﬁcant
associations between Ht and any of the TEG variables.
In uncomplicated babesiosis the clinical signs are
mostly attributable to the degree of the anemia.3 Since
the thromboelastogram is inﬂuenced by all components
of coagulation, the anemia in dogs suﬀering from bab-
esiosis has to be considered when evaluating the
results. Studies have reported that a decreased red cell
mass can lead to hypercoagulable tracings.32–34 How-
ever, it is still unclear whether this hypercoagulability
due to decreased red cell mass is a true reﬂection of in
vivo hypercoagulability.32–35 The anemia present in
canine babesiosis is due to hemolysis, caused by the
intra-erythrocytic parasite.36 The local disruption of
the red blood cells leads to the exposure of
intracellular stromal material, especially phospholipids,
which are expected to trigger the coagulation sys-
tem.37,38 Yet, ironically, 2 other studies evaluating in
vitro hemolysis (either mechanically induced or by
freeze-thawing) revealed decreased MA and G values
consistent with hypocoagulability.39,40
The signiﬁcantly higher mean ﬁbrinogen concentra-
tion in the babesiosis group as compared to the con-
trols, is consistent with an acute phase response.28
Platelet surfaces are densely populated with receptors
of which the glycoprotein IIb/IIIa complex (GPIIb/
IIIa) is the most prominent.41 In people, in vitro TEG
studies have reported that even with severe thrombocy-
topenia, thrombin-activated platelets bind to large
amounts of ﬁbrinogen via GPIIb/IIIa receptors, result-
ing in increased clot strength.20,42 Further evidence for
the concomitant activation of coagulation was sup-
ported by the mean AT activity, which was signiﬁ-
cantly lower in the babesiosis group. During severe
inﬂammation AT activity is decreased due to impaired
synthesis as result of a negative acute phase response,
degradation by granulocytic elastase, consumption as a
consequence of ongoing thrombin formation and
impairment due to the reduced availability of glycosa-
minoglycans.11,43 The D-dimer value was not signiﬁ-
cantly diﬀerent in the babesiosis group compared to
the controls and the D-dimer values of the babesiosis
group mostly remained within the normal range. The
TEG variables for ﬁbrinolysis (LY30 and LY60) were
also not signiﬁcantly diﬀerent and the babesiosis group
fell within the normal ranges, indicating that there was
no measurable activation of the ﬁbrinolytic system.
The PT was not signiﬁcantly diﬀerent between the
babesiosis and control group; however, the mean
aPTT was signiﬁcantly prolonged in the babesiosis
group compared to the control group. This study did
not further investigate the ﬁnding of a prolonged
aPTT in the presence of normal TEG variables. The
clinical relevance of this ﬁnding is questionable as the
diﬀerence was small with overlap between the groups.
This assay is also subject to large biological variation
and laboratory variance. A prolonged aPTT has been
reported in dogs with IMHA, in conjunction with
hypercoagulable TEG values.44 Prolonged aPTT has
also been reported in Bernese Mountain Dogs with
normal thromboelastograms and it was speculated
that this could be due to antiphospholipid antibod-
ies.45 The inﬂuence of antiphospholipid antibodies on
the aPTT values in our study is unknown; however, it
is likely that they play a role, since the anemia seen
in dogs with babesiosis is due to hemolysis, and the
local disruption of the red blood cells leads to the
exposure of intracellular stromal material, especially
phospholipids, which could trigger an immune
response.37,38
Limitations to this study included the small sample
size and the broad Ht range of the babesiosis dogs,
which makes it diﬃcult to draw inferences on the eﬀect
of Ht on the TEG variables. Consequently, future studies
should be conducted in which larger numbers of babesiosis
cases are categorized into several Ht ranges.
In summary, our study has shown that dogs suﬀer-
ing from uncomplicated babesiosis, caused by B. rossi,
have normal TEG variables in the face of severe
thrombocytopenia, anemia, and hyperﬁbrinogenemia.
This ﬁnding could indicate a normocoagulable state in
these patients due to a net result of the opposing
eﬀects on TEG of these abnormalities. However, the
normocoagulable state could also be as a result of the
inﬂammatory process that is present in babesiosis,
causing marked platelet activation which will bind to
the high concentration of ﬁbrinogen, resulting in
increased clot strength. Further research is required to
investigate this phenomenon in more detail.
Footnotes
a BD Vacutainer tube, S.A. Scientiﬁc, Bryanston, South Africa
b TEG® 5000 Thrombelastograph® Hemostasis System Haemo-
scope, Pro-Gen Diagnostics (Pty) Ltd, South Africa
c Advia 2120 Siemens, South Africa
d ST art® 4 analyzer DiagnosticaStago, Roche, South Africa
e Neoplastine® CI Plus reagent kit DiagnosticaStago reagent kit
f C.K. Prest® reagent kit DiagnosticaStago reagent kit
g Sta-Fib 2 reagent kit, DiagnosticaStago
h D-dimer single test, Nycocard Reader, ILEX South Africa
(Pty) Ltd
i Cobas Integra 400 plus, AT III cassette reagent, DiagnosticaS-
tago
j QIAmp® blood and tissue extraction kit, Qiagen, Hilden,
Germany
k StataCorp, College Station, TX
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